State of the art review: Intravenous fat emulsions: Current applications, safety profile, and clinical implications

Jay M. Mirtallo, Joseph F. Dasta, Kurt C. Kleinschmidt, Joseph Varon

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Objective: To review the current state of the science regarding intravenous fat emulsions (IVFEs), with an emphasis on their safety profile. Data sources: Articles were identified via a search of the MEDLINE database, including publications from 1979 to December 2009, using a search string that included the terms parenteral nutrition, lipid emulsion, fat emulsion, IVFE, safety, adverse effect, neonate intralipid, and terms describing a range of specific adverse events (AEs) such as pancreatitis. Study selection and data extraction: We selected articles that allowed us to compare the results of clinical trials involving delivery of medications via IVFEs with the historical use and effects of IVFEs in parenteral nutrition, with an emphasis on AEs. We focused on 2 drugs in current use that are administered intravenously in lipid emulsions: propofol and clevidipine. Data synthesis: Clearance of the fat particles in IVFEs is mediated by the enzyme lipoprotein lipase. AEs are more likely if the rate or duration of IVFE administration exceeds the enzyme's clearance capacity. AEs are also more likely after administration of a 10% IVFE formulation than a 20% formulation, because the higher concentration of free phospholipid in the 10% formulation interferes with lipoprotein lipase activity. AEs can be reduced by administering IVFEs at a dosage ≤2.5 g/kg/day and at a rate ≤0.11 g/kg/h. The anesthetic agent propofol, which is formulated in a 10% IVFE, has been used clinically for 25 years. Typical AEs associated with propofol use include infection, high plasma triglyceride concentrations, and pancreatitis. Recent clinical trials involving clevidipine, which is formulated in a 20% IVFE, have demonstrated a low rate of lipid-related AEs. Conclusions: The results of this review demonstrate that IVFEs are well tolerated when administered in accordance with guideline recommendations.

Original languageEnglish (US)
Pages (from-to)688-700
Number of pages13
JournalAnnals of Pharmacotherapy
Volume44
Issue number4
DOIs
StatePublished - Apr 2010

Fingerprint

Intravenous Fat Emulsions
Safety
Propofol
Lipoprotein Lipase
Parenteral Nutrition
Emulsions
Lipids
Pancreatitis
Fats
Clinical Trials
Information Storage and Retrieval
Enzymes
MEDLINE
Anesthetics
Publications

Keywords

  • Clevidipine
  • Lipid emulsion
  • Propofol
  • Safety

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

State of the art review : Intravenous fat emulsions: Current applications, safety profile, and clinical implications. / Mirtallo, Jay M.; Dasta, Joseph F.; Kleinschmidt, Kurt C.; Varon, Joseph.

In: Annals of Pharmacotherapy, Vol. 44, No. 4, 04.2010, p. 688-700.

Research output: Contribution to journalArticle

@article{10a15285ca9c489c983e0cabbf3238c5,
title = "State of the art review: Intravenous fat emulsions: Current applications, safety profile, and clinical implications",
abstract = "Objective: To review the current state of the science regarding intravenous fat emulsions (IVFEs), with an emphasis on their safety profile. Data sources: Articles were identified via a search of the MEDLINE database, including publications from 1979 to December 2009, using a search string that included the terms parenteral nutrition, lipid emulsion, fat emulsion, IVFE, safety, adverse effect, neonate intralipid, and terms describing a range of specific adverse events (AEs) such as pancreatitis. Study selection and data extraction: We selected articles that allowed us to compare the results of clinical trials involving delivery of medications via IVFEs with the historical use and effects of IVFEs in parenteral nutrition, with an emphasis on AEs. We focused on 2 drugs in current use that are administered intravenously in lipid emulsions: propofol and clevidipine. Data synthesis: Clearance of the fat particles in IVFEs is mediated by the enzyme lipoprotein lipase. AEs are more likely if the rate or duration of IVFE administration exceeds the enzyme's clearance capacity. AEs are also more likely after administration of a 10{\%} IVFE formulation than a 20{\%} formulation, because the higher concentration of free phospholipid in the 10{\%} formulation interferes with lipoprotein lipase activity. AEs can be reduced by administering IVFEs at a dosage ≤2.5 g/kg/day and at a rate ≤0.11 g/kg/h. The anesthetic agent propofol, which is formulated in a 10{\%} IVFE, has been used clinically for 25 years. Typical AEs associated with propofol use include infection, high plasma triglyceride concentrations, and pancreatitis. Recent clinical trials involving clevidipine, which is formulated in a 20{\%} IVFE, have demonstrated a low rate of lipid-related AEs. Conclusions: The results of this review demonstrate that IVFEs are well tolerated when administered in accordance with guideline recommendations.",
keywords = "Clevidipine, Lipid emulsion, Propofol, Safety",
author = "Mirtallo, {Jay M.} and Dasta, {Joseph F.} and Kleinschmidt, {Kurt C.} and Joseph Varon",
year = "2010",
month = "4",
doi = "10.1345/aph.1M626",
language = "English (US)",
volume = "44",
pages = "688--700",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "4",

}

TY - JOUR

T1 - State of the art review

T2 - Intravenous fat emulsions: Current applications, safety profile, and clinical implications

AU - Mirtallo, Jay M.

AU - Dasta, Joseph F.

AU - Kleinschmidt, Kurt C.

AU - Varon, Joseph

PY - 2010/4

Y1 - 2010/4

N2 - Objective: To review the current state of the science regarding intravenous fat emulsions (IVFEs), with an emphasis on their safety profile. Data sources: Articles were identified via a search of the MEDLINE database, including publications from 1979 to December 2009, using a search string that included the terms parenteral nutrition, lipid emulsion, fat emulsion, IVFE, safety, adverse effect, neonate intralipid, and terms describing a range of specific adverse events (AEs) such as pancreatitis. Study selection and data extraction: We selected articles that allowed us to compare the results of clinical trials involving delivery of medications via IVFEs with the historical use and effects of IVFEs in parenteral nutrition, with an emphasis on AEs. We focused on 2 drugs in current use that are administered intravenously in lipid emulsions: propofol and clevidipine. Data synthesis: Clearance of the fat particles in IVFEs is mediated by the enzyme lipoprotein lipase. AEs are more likely if the rate or duration of IVFE administration exceeds the enzyme's clearance capacity. AEs are also more likely after administration of a 10% IVFE formulation than a 20% formulation, because the higher concentration of free phospholipid in the 10% formulation interferes with lipoprotein lipase activity. AEs can be reduced by administering IVFEs at a dosage ≤2.5 g/kg/day and at a rate ≤0.11 g/kg/h. The anesthetic agent propofol, which is formulated in a 10% IVFE, has been used clinically for 25 years. Typical AEs associated with propofol use include infection, high plasma triglyceride concentrations, and pancreatitis. Recent clinical trials involving clevidipine, which is formulated in a 20% IVFE, have demonstrated a low rate of lipid-related AEs. Conclusions: The results of this review demonstrate that IVFEs are well tolerated when administered in accordance with guideline recommendations.

AB - Objective: To review the current state of the science regarding intravenous fat emulsions (IVFEs), with an emphasis on their safety profile. Data sources: Articles were identified via a search of the MEDLINE database, including publications from 1979 to December 2009, using a search string that included the terms parenteral nutrition, lipid emulsion, fat emulsion, IVFE, safety, adverse effect, neonate intralipid, and terms describing a range of specific adverse events (AEs) such as pancreatitis. Study selection and data extraction: We selected articles that allowed us to compare the results of clinical trials involving delivery of medications via IVFEs with the historical use and effects of IVFEs in parenteral nutrition, with an emphasis on AEs. We focused on 2 drugs in current use that are administered intravenously in lipid emulsions: propofol and clevidipine. Data synthesis: Clearance of the fat particles in IVFEs is mediated by the enzyme lipoprotein lipase. AEs are more likely if the rate or duration of IVFE administration exceeds the enzyme's clearance capacity. AEs are also more likely after administration of a 10% IVFE formulation than a 20% formulation, because the higher concentration of free phospholipid in the 10% formulation interferes with lipoprotein lipase activity. AEs can be reduced by administering IVFEs at a dosage ≤2.5 g/kg/day and at a rate ≤0.11 g/kg/h. The anesthetic agent propofol, which is formulated in a 10% IVFE, has been used clinically for 25 years. Typical AEs associated with propofol use include infection, high plasma triglyceride concentrations, and pancreatitis. Recent clinical trials involving clevidipine, which is formulated in a 20% IVFE, have demonstrated a low rate of lipid-related AEs. Conclusions: The results of this review demonstrate that IVFEs are well tolerated when administered in accordance with guideline recommendations.

KW - Clevidipine

KW - Lipid emulsion

KW - Propofol

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=77950616146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950616146&partnerID=8YFLogxK

U2 - 10.1345/aph.1M626

DO - 10.1345/aph.1M626

M3 - Article

C2 - 20332339

AN - SCOPUS:77950616146

VL - 44

SP - 688

EP - 700

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 4

ER -